Form DEF 14A ESPERION THERAPEUTICS For: 16 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Esperion Therapeutics Inc (ESPR)
The Esperion share price today is 1.910, view NASDAQ ESPR stock exchange data. Track the latest Esperion share price with real-time updates on ESPR stock performance including market cap, day range, 52-week range and dividend yield. Access ESPR charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.800
1.920
52 wk Range
0.693
4.175
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.8001.920
52 wk Range
0.6934.175
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ESPR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.743
Upside
+253.01%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has fared poorly over the last month
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics Inc Earnings Call Summary for Q4/2025
- Q4 revenue surged 144% YoY to $168.45M, driven by $124.7M collaboration revenue including Otsuka milestone payment.
- EPS of $0.22 missed forecast of $0.29 by 24%, though stock rose 7.24% in pre-market to $3.26 on revenue strength.
- US net product revenue grew 38% to $43.7M; company ended year with strong cash position and reduced debt levels.
- CEO Mayleben cited 2025 as best year on record; projects 2026 operating expenses of $225M-$255M including $15M stock compensation.
- Growth strategy focuses on new product launches and international expansion through strategic partnerships to sustain momentum.
Last Updated: 10-03-2026, 06:26 pm
Read Full TranscriptCompare ESPR to Peers and Sector
Metrics to compare | ESPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipESPRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.7x | −6.5x | −0.5x | |
PEG Ratio | −0.36 | 0.90 | 0.00 | |
Price/Book | −1.6x | 2.1x | 2.6x | |
Price / LTM Sales | 1.2x | 2.0x | 3.2x | |
Upside (Analyst Target) | 166.0% | 52.6% | 50.8% | |
Fair Value Upside | Unlock | 14.3% | 7.7% | Unlock |
Analyst Ratings
6 Buy
1 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.743
(+253.01% Upside)
Earnings
Latest Release
10-03-2026
EPS / Forecast
0.22 / 0.29
Revenue / Forecast
168.45M / 168.28M
FAQ
What Is the Esperion (ESPR) Share Price Today?
The Esperion share price today is 1.910.
What is the current Esperion (ESPR) share price and day range?
As of 30-04-2026, the Esperion share price is 1.910, with a previous close of 1.910. The share price has ranged from 1.800 to 1.920 today, while the 52-week range spans from 0.693 to 4.175.
What Is the Esperion Market Cap?
As of today, Esperion market cap is 487.780M.
What Is the Esperion (ESPR) Share Price Target?
The average 12-month share price target for Esperion is 6.743, with a high estimate of 16 and a low estimate of 1.77998. 6 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +253.01% Upside potential.
What Is Esperion's Earnings Per Share (TTM)?
The Esperion EPS (TTM) is -0.109.
When Is the Next Esperion Earnings Date?
Esperion will release its next earnings report on 07-05-2026.
From a Technical Analysis Perspective, Is ESPR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Esperion Trade On?
Esperion is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Esperion?
The stock symbol for Esperion is "ESPR."
How Many Times Has Esperion Stock Split?
Esperion has split 0 times.
How Many Employees Does Esperion Have?
Esperion has 294 employees.
What Is the ESPR Premarket Price?
ESPR's last pre-market stock price is 1.880. The pre-market share volume is 1,82,330.000, and the stock has changed by -0.030, or -1.570%.
What Is the ESPR After Hours Price?
ESPR's last after hours stock price is 1.907, the stock has changed by -0.004, or -0.180%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.